| Answers |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Investing > Fortune Favors The Brave But Beware The Pump And Dump |
|
Answers - Fortune Favors The Brave But Beware The Pump And Dump
All too often we jump in and suddenly find ourselves out of our depth. The stock we have just bought because it was going upwards in price quite nicely. And of course we did not wan According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product t to miss out did we? So we dived in as quick as we could. It has now suddenly stopped, gone downwards, whizzed past our stop loss (you did have one didn’t you?) and has now dropped ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in to at least 15- 20% lower than what we paid for it in the first place. And this has happened all in one day’s trading. So there you are bedazzled and bewildered and wondering what lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. the hell has gone wrong? More than likely you have been the victim, and have just been unfortunately snared up in a classic ”Pump and Dump.” I shall now inform you as to what has h here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe ppened. So you won’t get caught again next time. (Hopefully) Normally it is a stock that is in a very slow uptrend, with little bits of good news here and there in the media. This d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro is just enough to keep a bit of volume going, but hasn't been enough to attract the notice of the share market. Behind the scenes usually over a week or two, sometimes longer, one o ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc r two traders are busy buying up all the loose stock that is available. Usually at the lowest prices possible. Once the stock becomes harder to accumulate, they will offer a little easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi higher buying price just to keep the pot boiling quite nicely, still soaking up all the available stock. And when they have accumulated enough stock for their purpose the game is on nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically . A bigger buy order will go in (but not to large) offering higher prices. Sometimes this happens just before a pending news announcement is going to be made. This of course force and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ s the price upwards dramatically, which of course the market notices immediately. This is exactly what these traders have been waiting for. Because there is now a scarcity of stock ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi available, share prices will begin to start climbing steadily upwards. This is when traders begin to unload their stock at a trickle, then more again as more uniformed buyers (dare ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a I say suckers) compete against each other to buy the stock at inflated prices. All because they are frightened of missing out on the run to make huge profits. At this stage all of dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod the traders available leftover stocks are hitting the market at once which has the effect now of stalling the rise upwards. Now once this happens, the New Traders seeing the share p cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin rice start to slide backwards, they hang on hoping it is just a temporary adjustment in the stock before it continues upwards again. Or else they become panic stricken and start to tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen sell their stock, so as not to lose too much money, which of course has the effect of forcing the price downwards further still. Sometimes to a lower level than which it first start t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel ed at. Now I bet you are wondering where the original traders are now? They have gone, they have sold all of their stock at 100% profit if not more, usually just as the share price ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust started to drop downwards. And have now begun quietly buying back that same stock at bargain basement prices. Preparing themselves to do it all again at a later date. How do I know y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products this?? Because I have found out the hard way, not just once but twice. So I am talking from bitter experience. And be careful, it hasn’t stopped yet, because it is still going on . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de in today's stock market. One classic place to find these traders in action is in a chat room where they are busy "ramping" a particular stock or giving out red hot tips. Some tips elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip are of course genuine, but remember ”Always Do Your Own Research.” If things look too good to be true or you are suspicious, ignore that tip. It could save you money and heartaches tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Joint Venture 101 - The Quickest Way To Build Your eBusiness - PART 1 A Guide to Finding Credit Cards Online
|